363 related articles for article (PubMed ID: 25801913)
21. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Colarossi L; Memeo L; Colarossi C; Aiello E; Iuppa A; Espina V; Liotta L; Mueller C
Proteomics Clin Appl; 2014 Dec; 8(11-12):924-31. PubMed ID: 25091122
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway.
Li X; Guo Y; Kuang X; Zhao L; Li H; Cheng B; Wang W; Zhang Z; Liu P; Wang J
Life Sci; 2019 Apr; 223():146-157. PubMed ID: 30876940
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Expression Signature of Histone Deacetylases (HDACs) in Mesenchymal Stem Cells from Multiple Myeloma and Normal Donors.
Ahmadvand M; Noruzinia M; Soleimani M; Abroun S
Asian Pac J Cancer Prev; 2016; 17(7):3605-10. PubMed ID: 27510016
[TBL] [Abstract][Full Text] [Related]
25. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase and GATA-binding factor 6 regulate arterial remodeling in angiotensin II-induced hypertension.
Kim GR; Cho SN; Kim HS; Yu SY; Choi SY; Ryu Y; Lin MQ; Jin L; Kee HJ; Jeong MH
J Hypertens; 2016 Nov; 34(11):2206-19. PubMed ID: 27512969
[TBL] [Abstract][Full Text] [Related]
27. Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9.
Lenoir O; Flosseau K; Ma FX; Blondeau B; Mai A; Bassel-Duby R; Ravassard P; Olson EN; Haumaitre C; Scharfmann R
Diabetes; 2011 Nov; 60(11):2861-71. PubMed ID: 21953612
[TBL] [Abstract][Full Text] [Related]
28. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
29. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
30. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
31. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
32. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
33. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
[TBL] [Abstract][Full Text] [Related]
34. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death.
Ohoka N; Yoshii S; Hattori T; Onozaki K; Hayashi H
EMBO J; 2005 Mar; 24(6):1243-55. PubMed ID: 15775988
[TBL] [Abstract][Full Text] [Related]
35. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma.
Liu H; Xiong C; Liu J; Sun T; Ren Z; Li Y; Geng J; Li X
Biomed Pharmacother; 2020 May; 125():110005. PubMed ID: 32070879
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J; Suzuki R; Mazitschek R; Gorgun G; Ghosh B; Cirstea D; Hu Y; Mimura N; Ohguchi H; Cottini F; Jakubikova J; Munshi NC; Haggarty SJ; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2014 Mar; 28(3):680-9. PubMed ID: 23913134
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Wanek J; Gaisberger M; Beyreis M; Mayr C; Helm K; Primavesi F; Jäger T; Di Fazio P; Jakab M; Wagner A; Neureiter D; Kiesslich T
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321986
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death.
Guida N; Laudati G; Galgani M; Santopaolo M; Montuori P; Triassi M; Di Renzo G; Canzoniero LM; Formisano L
Toxicol Appl Pharmacol; 2014 Oct; 280(1):190-8. PubMed ID: 25068794
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
